Concepedia

Kristin Colson

KC

Statistics

Publications

6

Citations

193

H-Index

6

Active since

1994

Affiliations

Dana-Farber Cancer Institute(Current)

University of Virginia

City of Hope

University of Michigan

Moffitt Cancer Center

Kristin Colson is an author at Dana-Farber Cancer Institute specializing in medicine, metabolomics, and drug analysis.

Top concepts

Publications per year

1994–2015

6

Publications

6

Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life

Rachid Baz, Huamao Mark Lin, Ai Hui et al. · Supportive Care in Cancer · 2015 · 67 citations

, , +11

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

Paul G. Richardson, Sagar Lonial, Andrzej Jakubowiak et al. · Blood · 2007 · 39 citations

A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma.

Paul G. Richardson, R Schlossman, Nikhil C. Munshi et al. · Blood · 2005 · 35 citations

Isolation and identification of the major urinary metabolite of m-chlorophenylpiperazine in the rat.

Robert F. Mayol, C A Cole, Kristin Colson et al. · Drug Metabolism and Disposition · 1994 · 21 citations

, , +6

Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.

Paul G. Richardson, Andrzej Jakubowiak, J. Wolf et al. · Blood · 2007 · 18 citations

Rows per page

1–5 of 6